^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

Excerpt:
Here we described the emergence of an ALK F1245C mutation in an advanced ALK+ NSCLC patient (EML4-ALK variant 3a/b) who developed slow disease progression after a durable response to crizotinib….This is the first patient report that ALK F1245C is an acquired resistance mutation to crizotinib...
DOI:
10.1016/j.lungcan.2015.11.023